|
NCT04422275
|
Coronavirus Smell Therapy for Anosmia Recovery |
Withdrawn |
Phase 2 |
Jun/01/2021 |
Dec/31/2023 |
- Alternative id - PA-18-334
- Interventions - Drug: Budesonide|Behavioral: High-Concentration Essential Oil|Drug: Placebo|Behavioral: Low-Concentration Essential Oil
- Study type - Interventional
- Study results - No Results Available
- Locations - Washington University, Saint Louis, Missouri, United States
- Study designs - Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 0
- Age - 18 Years to 85 Years (Adult, Older Adult)
- Outcome measures - University of Pennsylvania Smell Identification Test (UPSIT)|Questionnaire of Olfactory Disorders-Negative Statements (QOD-NS).|Global Rating of Smell.|Global Rating of Smell Change.
|
|
NCT04331470
|
Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19 |
Recruiting |
Phase 2|Phase 3 |
Apr/04/2020 |
May/20/2020 |
- Alternative id - 97548
- Interventions - Drug: Levamisole Pill + Budesonide+Formoterol inhaler|Drug: Lopinavir/Ritonavir + hydoxychloroquine
- Study type - Interventional
- Study results - No Results Available
- Locations - Vali-Asr Hospital, Fasa, Fars, Iran, Islamic Republic of
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 30
- Age - 15 Years to 100 Years (Child, Adult, Older Adult)
- Outcome measures - Clear chest CT-scan|PCR test|Physical statues of patient
|
|
NCT04952389
|
Acupuncture Therapy for COVID-Related Olfactory Loss |
Recruiting |
Not Applicable |
Dec/07/2021 |
Aug/01/2023 |
- Alternative id - 21-003531
- Interventions - Device: Acupuncture Therapy|Drug: Budesonide|Other: Olfactory Training
- Study type - Interventional
- Study results - No Results Available
- Locations - Mayo Clinic in Rochester, Rochester, Minnesota, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 100
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Change in UPSIT scores|Change in patient-reported subjective olfactory loss|Change in Sino-Nasal Outcome Test (SNOT-22)
|
|
NCT05269030
|
Ivermectin Nasal Drops in Post COVID Parosmia |
Not yet recruiting |
Phase 2 |
Apr/01/2022 |
Dec/01/2022 |
- Alternative id - 1/2022 PHAR
- Interventions - Drug: Ivermectin Topical|Drug: Budesonide Nasal
- Study type - Interventional
- Study results - No Results Available
- Locations - Menoufia Faculty of Medicine, Shibīn Al Kawm, Menoufia, Egypt
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 60
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Comparison between the pre and post treatment values|Comparison between case and control groups regarding the post treatment results|Assessment of the side effects of Ivermectin nasal drops
|
|
NCT05269017
|
Vitamin D Nasal Drops in Post COVID Parosmia |
Not yet recruiting |
Phase 2 |
Apr/01/2022 |
Dec/01/2022 |
- Alternative id - 1/2022 PHAR2
- Interventions - Drug: Vitamin D3|Drug: Budesonide nasal spray
- Study type - Interventional
- Study results - No Results Available
- Locations - Menoufia Faculty of Medicine, Shibīn Al Kawm, Menoufia, Egypt
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 60
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Comparison between the pre and post treatment values|Comparison between case and control groups regarding the post treatment results|Assessment of the side effects of Ivermectin nasal drops
|
|
NCT05055414
|
Arformoterol/Budesonide for COVID-19 |
Not yet recruiting |
Phase 2 |
Nov/01/2021 |
Nov/01/2022 |
- Alternative id - KUP-UI030-231
- Interventions - Drug: UI030
- Study type - Interventional
- Study results - No Results Available
- Locations -
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
- Enrollment - 140
- Age - 19 Years and older (Adult, Older Adult)
- Outcome measures - Time to Clinical Improvement on World Health Organization (WHO) Ordinal Scale|World Health Organization (WHO) Ordinal Scale for Clinical Improvement|World Health Organization (WHO) Ordinal Scale change|Clinical cure rate
|
|
NCT04416399
|
STerOids in COVID-19 Study |
Terminated |
Phase 2 |
Jul/16/2020 |
Jan/12/2021 |
- Alternative id - STOIC study
- Interventions - Drug: Budesonide dry powder inhaler
- Study type - Interventional
- Study results - No Results Available
- Locations - Oxford Respiratory Trials Unit, Oxford, Oxfordshire, United Kingdom
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 146
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Emergency department attendance of hospitalisation related to COVID-19|Body temperature|Blood oxygen saturation level|Symptoms as assessed by common cold questionnaire|Symptoms as assessed by FluPro questionnaire|Nasal/throat swab SARS-CoV-2 viral load
|
|
NCT04361474
|
Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity |
Completed |
Phase 3 |
May/18/2020 |
Jun/25/2021 |
- Alternative id - MDL_2020_10
- Interventions - Drug: Budesonide Nasal|Other: Physiological serum
- Study type - Interventional
- Study results - No Results Available
- Locations - Amélie YAvchitz, Paris, France
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment
- Enrollment - 120
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Patient with more than 2 points on the ODORATEST
|
|
NCT04355637
|
Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia |
Completed |
Phase 4 |
Apr/21/2020 |
Jun/30/2021 |
- Alternative id - TACTIC-COVID|2020-001616-18
- Interventions - Drug: Inhaled budesonide
- Study type - Interventional
- Study results - No Results Available
- Locations - Hospital de Infecciosas "Francisco Javier Muñiz", Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|CEMIC (Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"), Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Hospital de Rehabilitación Respiratoria "María Ferrer", Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina|Hospital Donación "Francisco Santojanni", Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina|Clínica Monte Grande, Monte Grande, Buenos Aires, Argentina|Hospital Centro de Salud Zenón J. Santillán, San Miguel De Tucumán, Tucumán, Argentina|Hospital San Juan de Dios, La plata, Argentina|Hospital de Santiago, Santiago De Compostela, A Coruña, Spain|Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic of Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 120
- Age - 18 Years to 79 Years (Adult, Older Adult)
- Outcome measures - Proportion of patients in both arms fulfilling the criteria for treatment failure|ICU admission|ICU refusal|Occurrence of complications|lactate dehydrogenase (LDH)|C Reactive Protein (CRP)|ferritin|D-dimer|leukocyte counts
|
|
NCT04727424
|
Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms |
Recruiting |
Phase 3 |
Jan/19/2021 |
Nov/01/2023 |
- Alternative id - TOGETHER_2
- Interventions - Drug: Fluvoxamine Maleate 100 MG [Luvox]|Drug: Budesonide Powder|Drug: Placebo (mild disease)|Drug: Peginterferon Lambda-1a|Drug: Placebo (SpO2 < 94%)
- Study type - Interventional
- Study results - No Results Available
- Locations - City of Betim, Betim, MG, Brazil|Hospital e Maternidade Santa Rita, Contagem, MG, Brazil|City of Governador Valadares, Governador Valadares, MG, Brazil|City of Ibirité, Ibirité, MG, Brazil|City of Nova Lima, Nova Lima, MG, Brazil|City of Santa Luzia, Santa Luzia, MG, Brazil|City of Sete Lagoas, Sete Lagoas, MG, Brazil|CARDRESEARCH - Cardiologia Assistencial e de Pesquisa, Belo Horizonte, Minas Gerais, Brazil|City of Brumadinho, Brumadinho, Minas Gerais, Brazil|City of Igarapé, Igarapé, Minas Gerais, Brazil|Centro Universitário FIPMOC, Montes Claros, Minas Gerais, Brazil|Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, Brazil
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 4669
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Rate of fluvoxamine + budesonide, peginterferon Lambda and fluvoxamine in changing the need for emergency care AND observation for more than 06 hours due to the worsening of COVID-19;|Rate of fluvoxamine + budesonide, peginterferon Lambda and fluvoxamine in changing the need for Hospitalization due to COVID-19 progression and related complications, including lower respiratory tract infection (LRTI)|Change in viral load on day 03 and 07 after randomization (interferon lambda arm)|Time to clinical changes (up to 28 days of randomization), defined as greater than 50% symptoms changing in reference to baseline symptoms)|Time to clinical failure, defined as time to need for hospitalization due to the clinical progression of COVID-19 or associated complications.|Number of days with respiratory symptoms since randomization|Rate of all-cause hospitalizations|Rate of COVID-19 related hospitalizations|Number of days on Mechanical Ventilator|Number of Days on Intensive Care Unit|Number of days on hospitalizations|Health and Functioning after COVID-19 disease|WHO ordinal scale for clinical improvement|Number of days on respiratory Symptoms|Adherence of Study drug
|
|
NCT04964414
|
Treatment of Pediatric Patients That Lost Sense of Smell Due to COVID-19 |
Recruiting |
Phase 1|Phase 2 |
Sep/30/2021 |
Dec/01/2024 |
- Alternative id - STUDY21050012
- Interventions - Other: Smell Retraining|Drug: Budesonide
- Study type - Interventional
- Study results - No Results Available
- Locations - UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 60
- Age - 6 Years to 21 Years (Child, Adult)
- Outcome measures - Change in University of Pennsylvania Smell Identification Test (UPSIT) score from baseline to first follow-up|Change in Sino-nasal Outcome Test-22 (SNOT-22) score from baseline to first follow-up|Change in loss of smell question score from baseline to first follow-up|Change in University of Pennsylvania Smell Identification Test (UPSIT) score from baseline to 6 month follow-up|Change in Sino-nasal Outcome Test-22 (SNOT-22) score from baseline to 6 month follow-up|Change in University of Pennsylvania Smell Identification Test (UPSIT) score from baseline to 12 month follow-up|Change in Sino-nasal Outcome Test-22 (SNOT-22) score from baseline to 12 month follow-up
|
